Simon Barry J. 4

4 · ImmunityBio, Inc. · Filed Feb 24, 2026

Form 4

Period: 2026-02-20

Director

Transactions

Sale
Common Stock
[F1]
2026-02-20$9.25/sh−10,000$92,500→ 3,081,604 total
Exercise/Conversion
Common Stock
[F2]
2026-02-22+15,243→ 3,096,847 total
Tax Payment
Common Stock
[F3]
2026-02-22$8.70/sh−6,026$52,426→ 3,090,821 total
Sale
Common Stock
[F1][F4]
2026-02-23$10.25/sh−165,000$1,691,102→ 2,925,821 total
Exercise/Conversion
Restricted Stock Units
[F2][F5]
2026-02-22−15,243→ 15,245 total
→ Common Stock (15,243 underlying)

Footnotes (5)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.
[F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.
[F3]On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.
[F4]Represents the weighted average share price of an aggregate total of 165,000 shares sold in the price range of $9.89 to $10.635 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F5]Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

Signature

/s/ Philip LoScalzo, as Attorney-in-Fact|2026-02-24

Documents

1 file